Application of puerarin crystal V-type substance for preventing and treating diabetic cardiomyopathy

The invention belongs to the technical field of medicines, and relates to a puerarin crystal V type substance and application of a composition thereof in preventing, treating and/or relieving diabetic cardiomyopathy. Particularly insulin resistance, myocardial hypertrophy and heart failure caused by diabetes mellitus; the diabetes mellitus is type 2 diabetes mellitus or/and type 1 diabetes mellitus; the puerarin crystal V-type substance is taken as an active component, and the puerarin crystal V-type substance is taken orally by 1-1000 mg/kg per person every day and is combined with other active components and excipients to prepare the clinical solid medicine form. Compared with a puerarin raw material medicine (crystal form IV) and a puerarin injection on the market, the puerarin crystal form V substance disclosed by the invention has the effects of preventing and treating diabetic cardiomyopathy and has obvious advantages..

Medienart:

Patent

Erscheinungsjahr:

2023

Erschienen:

2023

Enthalten in:

Europäisches Patentamt - (2023) vom: 24. Okt. Zur Gesamtaufnahme - year:2023

Sprache:

Englisch

Beteiligte Personen:

DU GUANHUA [VerfasserIn]
LYU YANG [VerfasserIn]
FANG LIANHUA [VerfasserIn]
YUAN TIANYI [VerfasserIn]
WANG SHOUBAO [VerfasserIn]
XING CHENG [VerfasserIn]
SUN SHUCHAN [VerfasserIn]
WANG RANRAN [VerfasserIn]
GONG DIFEI [VerfasserIn]

Links:

Volltext [kostenfrei]

Themen:

Sonstige Themen:
615
A61K: Preparations for medical, dental, or toilet purpose (...)
A61P: Specific therapeutic activity of chemical compounds (...)
che

Anmerkungen:

Source: www.epo.org (no modifications made), First posted: 2023-10-24, Last update posted on www.tib.eu: 2024-01-22, Last updated: 2024-01-26

Patentnummer:

CN116919943

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

EPA018917356